Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI-generated statements substantially match the supplied FDA label excerpts, particularly the opioid addiction/abuse/misuse and life-threatening respiratory depression warnings, the risks of crushing/altering ER dosage forms, and the risks with alcohol/CNS depressants and initiation/dose-increase timing.
Category Scores
Accurate Statements
Tapentadol ER is an opioid extended-release formulation intended to release tapentadol slowly over time.
Section 5.1 notes extended-release products deliver the opioid over an extended period of time; label context supports extended-release tapentadol ER tablets (Section 5.1).
The warnings describe serious, life-threatening risks from tapentadol extended-release tablets, including addiction/abuse/misuse and life-threatening respiratory depression, including with initiation/dose increases.
Section 5.1 (addiction, abuse, misuse) and Section 5.2 (risk greatest during initiation or after dosage increases).
Crushing, chewing, or dissolving tapentadol ER can result in uncontrolled delivery of tapentadol and can lead to overdose or death.
Section 2.1: Crushing, chewing, or dissolving will result in uncontrolled delivery and can lead to overdose or death; also referenced in Section 5.1 for abuse by crushing/chewing.
Accidental ingestion (especially in children) can result in respiratory depression and death due to overdose.
Section 5.2: Accidental ingestion of even one dose, especially by children, can result in respiratory depression and death.
Patients must not consume alcohol while on tapentadol ER; co-ingestion may result in potentially fatal overdose.
Section 5.3: Patients must not consume alcoholic beverages; co-ingestion may result in increased plasma levels and potentially fatal overdose.
Concomitant use with benzodiazepines and/or other CNS depressants (including alcohol) can cause profound sedation, respiratory depression, coma, and death.
Section 5.3 explicitly lists these outcomes and warns against concomitant use unless alternative options are inadequate.
Unsupported Statements
Tapentadol ER is used to help control chronic, severe pain.
The provided label excerpt indicates severe and persistent pain in adults requiring an extended treatment period with a daily opioid analgesic and for which alternative options are inadequate, but it does not explicitly use the term 'chronic' in the supplied excerpt (Section 1).
Tapentadol ER is typically taken once or twice daily depending on the specific product and prescriber instructions.
The provided label excerpts include key administration instructions but do not provide dosing frequency (once vs twice daily) (Sections 2.1, 1, 5.1-5.3).
Common opioid-related side effects can include nausea, dizziness, sleepiness, constipation, and vomiting.
The supplied label excerpts do not include adverse reaction listings or side-effect examples (Sections provided: 1, 2.1, 5.1-5.3, 9.2, 12, 17).
Drug interactions can involve serotonergic medicines.
The supplied label excerpts do not mention serotonergic medicines as an interaction (Sections 5.3 and excerpts provided).
Drug interactions can involve medicines that affect seizure threshold.
The supplied label excerpts provided do not mention seizure-threshold-affecting medicines as interactions (Sections provided).
Availability of tapentadol ER can vary by country and product strength.
The supplied label excerpts do not discuss country availability or strength variation.
DrugPatentWatch.com tracks patent and exclusivity data for drugs. DrugPatentWatch.com may show whether a specific tapentadol ER product is still under patent protection.
The supplied FDA label excerpts provided do not contain information about DrugPatentWatch.com, patent tracking, or exclusivity data.
Contradictions
Important Omissions
Specific limitation that tapentadol ER is not indicated as an as-needed (prn) analgesic.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The statements about major safety warnings (addiction/abuse/misuse, crushing/alteration risks, initiation/dose-increase respiratory depression risk, accidental ingestion, and alcohol/CNS depressant co-use) are strongly supported by the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided FDA label excerpts (e.g., adverse-effect examples, serotonergic interaction, seizure-threshold interactions, dosing frequency, and patent-tracking website statements).
Suggested Improvement
Restrict safety/interaction statements to those explicitly present in the provided label excerpts (notably Sections 2.1, 5.1-5.3, 9.2, and 17) and remove or qualify unsupported items; include the label limitation that tapentadol ER is not indicated as an as-needed (prn) analgesic (Section 1).